CN105246915A - Hgf抗体及含有其的组合物 - Google Patents

Hgf抗体及含有其的组合物 Download PDF

Info

Publication number
CN105246915A
CN105246915A CN201480026978.3A CN201480026978A CN105246915A CN 105246915 A CN105246915 A CN 105246915A CN 201480026978 A CN201480026978 A CN 201480026978A CN 105246915 A CN105246915 A CN 105246915A
Authority
CN
China
Prior art keywords
seqidno
antibody
sequence
heavy chain
variable heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026978.3A
Other languages
English (en)
Chinese (zh)
Inventor
B·H·达特扎尔
K·安德森
B·R·克瓦希维奇
A·L·菲尔德豪斯
J·A·莱瑟姆
L·F·加西亚-马提尼兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck Seattle Biopharmaceuticals Inc
Original Assignee
Alder Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alder Biopharmaceuticals Inc filed Critical Alder Biopharmaceuticals Inc
Publication of CN105246915A publication Critical patent/CN105246915A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480026978.3A 2013-03-14 2014-03-14 Hgf抗体及含有其的组合物 Pending CN105246915A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361781643P 2013-03-14 2013-03-14
US201361782868P 2013-03-14 2013-03-14
US61/781,643 2013-03-14
US61/782,868 2013-03-14
PCT/US2014/029163 WO2014153117A2 (en) 2013-03-14 2014-03-14 Antibodies to hgf and compositions containing

Publications (1)

Publication Number Publication Date
CN105246915A true CN105246915A (zh) 2016-01-13

Family

ID=51581767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026978.3A Pending CN105246915A (zh) 2013-03-14 2014-03-14 Hgf抗体及含有其的组合物

Country Status (7)

Country Link
EP (1) EP2964673A4 (ko)
JP (1) JP2016516052A (ko)
KR (1) KR20150140685A (ko)
CN (1) CN105246915A (ko)
CA (1) CA2904743A1 (ko)
TW (2) TW201438737A (ko)
WO (2) WO2014153166A2 (ko)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868A (zh) * 2017-03-01 2017-05-24 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
WO2021062960A1 (zh) * 2019-09-30 2021-04-08 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
WO2022228514A1 (zh) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 抗人白血病抑制因子抗体及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN115279375A (zh) 2019-11-05 2022-11-01 艾伯维公司 用于以navitoclax治疗骨髓纤维化和mpn相关病症的给药方案

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (en) * 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor
CN1964738A (zh) * 2004-04-15 2007-05-16 加拉克西生物技术有限责任公司 针对肝细胞生长因子的单克隆抗体
CN101460520A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
CN101600793A (zh) * 2006-05-19 2009-12-09 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
AU2007254942B2 (en) * 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
KR101196184B1 (ko) * 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9539324B2 (en) * 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005017107A2 (en) * 2003-07-18 2005-02-24 Amgen Inc. Specific binding agents to hepatocyte growth factor
CN1964738A (zh) * 2004-04-15 2007-05-16 加拉克西生物技术有限责任公司 针对肝细胞生长因子的单克隆抗体
CN101600793A (zh) * 2006-05-19 2009-12-09 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
CN101460520A (zh) * 2006-06-02 2009-06-17 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEN PY.等: "A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma", 《NEURO-ONCOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106699868A (zh) * 2017-03-01 2017-05-24 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
WO2021062960A1 (zh) * 2019-09-30 2021-04-08 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同治疗肾癌中的应用
WO2022228514A1 (zh) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 抗人白血病抑制因子抗体及其用途

Also Published As

Publication number Publication date
JP2016516052A (ja) 2016-06-02
TW201444868A (zh) 2014-12-01
WO2014153117A2 (en) 2014-09-25
TW201438737A (zh) 2014-10-16
WO2014153117A3 (en) 2015-01-08
CA2904743A1 (en) 2014-09-25
WO2014153166A2 (en) 2014-09-25
KR20150140685A (ko) 2015-12-16
EP2964673A4 (en) 2017-02-22
WO2014153117A9 (en) 2014-11-27
EP2964673A2 (en) 2016-01-13
WO2014153166A3 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
US20190085066A1 (en) Antibodies to hgf and compositions containing
CN102740888B (zh) Il-6抗体及其用途
CN101754772B (zh) 针对il-6的抗体及其用途
CN102292106B (zh) Il-6抗体及其用途
US9783603B2 (en) Therapeutic use of antibodies to HGF
JP2021104030A (ja) 抗ｅｇｆｒ抗体及び抗体薬物コンジュゲート
US20140271464A1 (en) Therapeutic use of antibodies to hgf
ES2435727T3 (es) Anticuerpo contra PDGFR-alfa para uso en el tratamiento de tumores
CN105246915A (zh) Hgf抗体及含有其的组合物
EP2377555A2 (en) Antibodies against vascular endothelial growth factor receptor-1
CN103619879A (zh) 抗ngf组合物及其用途
JP2009120583A (ja) 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
KR20170065466A (ko) 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체
CA3166328A1 (en) Tgf-beta inhibitors and use thereof
US11365250B2 (en) Compositions and methods for cancer therapy
KR20230155978A (ko) 항-CD300c 항체 또는 이의 항원 결합 단편 및 그의 퇴행성 뇌 질환 예방 또는 치료용 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160113

WD01 Invention patent application deemed withdrawn after publication